Antibodies to pre-erythrocytic Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children

Journal of Infectious Diseases

Volumn 197, Issue 4, 2008, Pages 519-526

  John, Chandy C ^a   Tande, Aaron J ^a   Moormann, Ann M ^b   Sumba, Peter O ^d   Lanar, David E ^c   Min, Xinan M ^a   Kazura, James W ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; HEMOGLOBIN; IMMUNOGLOBULIN G; THROMBOSPONDIN;

ARTICLE; ERYTHROCYTE; FEMALE; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALARIA; MALE; MORBIDITY; PARASITEMIA; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SCHOOL CHILD;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; ENDEMIC DISEASES; HUMANS; IMMUNOGLOBULIN G; INCIDENCE; INFANT; KENYA; LONGITUDINAL STUDIES; MALARIA, FALCIPARUM; PARASITEMIA; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; SPOROZOITES;

EID: 40049102809     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/526787     Document Type: Article

References (37)

1. Cohen S, McGregor IA, Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature 1961; 192:733-7.
2. John CC, Sumba PO, Ouma JH, Nahlen BL, King CL, Kazura JW. Cytokine responses to Plasmodium falciparum liver-stage antigen 1 vary in rainy and dry seasons in highland Kenya. Infect Immun 2000; 68:5198-204.
3. + T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med 2004; 10:406-10.
4. + T cells and antibodies required for immunity to malaria sporozoites. Nature 1987; 330:664-6.
5. Doolan DL, Hoffman SL. The complexity of protective immunity against liver-stage malaria. J Immunol 2000; 165:1453-62.
6. Chatterjee S, Wery M, Sharma P, Chauhan VS. A conserved peptide sequence of the Plasmodium falciparum circumsporozoite protein and antipeptide antibodies inhibit Plasmodium berghei sporozoite invasion of Hep-G2 cells and protect immunized mice against P. berghei sporozoite challenge. Infect Immun 1995; 63:4375-81.
7. + T cells to sporozoite-induced protection against malaria. Immunology 1993; 80:1-5.
8. Stewart MJ, Nawrot RJ, Schulman S, Vanderberg JP. Plasmodium berghei sporozoite invasion is blocked in vitro by sporozoite-immobilizing antibodies. Infect Immun 1986; 51:859-64.
9. Wang R, Charoenvit Y, Corradin G, et al. Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine. J Immunol 1995; 154:2784-93.
10. John CC, Moormann AM, Pregibon DC, et al. Correlation of high levels of antibodies to multiple pre-erythrocytic Plasmodium falciparum antigens and protection from infection. Am J Trop Med Hyg 2005; 73:222-8.
11. Bloland PB, Boriga DA, Ruebush TK, et al. Longitudinal cohort study of the epidemiology of malaria infections in an area of intense malaria transmission. II. Descriptive epidemiology of malaria infection and disease among children. Am J Trop Med Hyg 1999; 60:641-8.
12. Alonso PL. Malaria: deploying a candidate vaccine (RTS,S/AS02A) for an old scourge of humankind. Int Microbiol 2006; 9:83-93.
13. Moorthy VS, McConkey S, Roberts M, et al. Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 2003; 21:1995-2002.
14. Prieur E, Gilbert SC, Schneider J, et al. A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses. Proc Natl Acad Sci U S A 2004; 101:290-5.
15. John CC, Moormann AM, Sumba PO, Ofulla AV, Pregibon DC, Kazura JW. Gamma interferon responses to Plasmodium falciparum liver-stage antigen 1 and thrombospondin-related adhesive protein and their relationship to age, transmission intensity, and protection against malaria. Infect Immun 2004; 72:5135-42.
16. Chougnet C, Lepers JP, Astagneau P, Rason MD, Savel J, Deloron P. Lymphoproliferative responses to synthetic peptides from merozoite ring-infected erythrocyte surface antigen and circumsporozoite protein: a longitudinal study during a falciparum malaria episode. Am J Trop Med Hyg 1991; 45:560-6.
17. Fidock DA, Gras-Masse H, Lepers JP, et al. Plasmodium falciparum liver stage antigen-1 is well conserved and contains potent B and T cell determinants. J Immunol 1994; 153:190-204.
18. Gysin J, Barnwell J, Schlesinger DH, Nussenzweig V, Nussenzweig RS. Neutralization of the infectivity of sporozoites of Plasmodium knowlesi by antibodies to a synthetic peptide. J Exp Med 1984; 160:935-40.
19. Hollingdale MR, Nardin EH, Tharavanij S, Schwartz AL, Nussenzweig RS. Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells; an in vitro assay of protective antibodies. J Immunol 1984; 132:909-13.
20. Charoenvit Y, Fallarme V, Rogers WO, et al. Development of two monoclonal antibodies against Plasmodium falciparum sporozoite surface protein 2 and mapping of B-cell epitopes. Infect Immun 1997; 65:3430-7.
21. Muller HM, Reckmann I, Hollingdale MR, Bujard H, Robson KJ, Crisanti A. Thrombospondin related anonymous protein (TRAP) of Plasmodium falciparum binds specifically to sulfated glycoconjugates and to HepG2 hepatoma cells suggesting a role for this molecule in sporozoite invasion of hepatocytes. Embo J 1993; 12:2881-9.
22. Schofield L, Ferreira A, Altszuler R, Nussenzweig V, Nussenzweig RS. Interferon-gamma inhibits the intrahepatocytic development of malaria parasites in vitro. J Immunol 1987; 139:2020-5.
23. + T-cell- and gamma interferon-dependent protection against murine malaria by immunization with linear synthetic peptides from a Plasmodium yoelii 17-kilodalton hepatocyte erythrocyte protein. Infect Immun 1999; 67:5604-14.
24. Sedegah M, Hedstrom R, Hobart P, Hoffman S. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci U S A 1994; 91:9866-70.
25. Frevert U, Sinnis P, Cerami C, Shreffler W, Takacs B, Nussenzweig V. Malaria circumsporozoite protein binds to heparan sulfate proteoglycans associated with the surface membrane of hepatocytes. J Exp Med 1993; 177:1287-98.
26. Sultan AA, Thathy V, Frevert U, et al. TRAP is necessary for gliding motility and infectivity of plasmodium sporozoites. Cell 1997; 90:511-22.
27. Kurtis JD, Hollingdale MR, Luty AJ, Lanar DE, Krzych U, Duffy PE. Pre-erythrocytic immunity to Plasmodium falciparum: the case for an LSA-1 vaccine. Trends Parasitol 2001; 17:219-23.
28. Jafarshad A, Dziegiel MH, Lundquist R, Nielsen LK, Singh S, Druilhe PL. A novel antibody-dependent cellular cytotoxicity mechanism involved in defense against malaria requires costimulation of monocytes FcgammaRII and FcgammaRIII. J Immunol 2007; 178:3099-106.
29. Lundquist R, Nielsen LK, Jafarshad A, et al. Human recombinant antibodies against Plasmodium falciparum merozoite surface protein 3 cloned from peripheral blood leukocytes of individuals with immunity to malaria demonstrate antiparasitic properties. Infect Immun 2006; 74:3222-31.
30. Migot-Nabias F, Deloron P, Ringwald P, et al. Immune response to Plasmodium falciparum liver stage antigen-1: geographical variations within Central Africa and their relationship with protection from clinical malaria. Trans R Soc Trop Med Hyg 2000; 94:557-62.
31. John CC, Zickafoose JS, Sumba PO, King CL, Kazura JW. Antibodies to the Plasmodium falciparum antigens circumsporozoite protein, thrombospondin-related adhesive protein, and liver-stage antigen 1 vary by ages of subjects and by season in a highland area of Kenya. Infect Immun 2003; 71:4320-5.
32. Kitua AY, Urassa H, Wechsler M, et al. Antibodies against Plasmodium falciparum vaccine candidates in infants in an area of intense and perennial transmission: relationships with clinical malaria and with entomological inoculation rates. Parasite Immunol 1999; 21:307-17.
33. Wongsrichanalai C, Webster HK, Permpanich B, Chuanak N, Ketrangsri S. Naturally acquired circumsporozoite antibodies and their role in protection in endemic falciparum and vivax malaria. Am J Trop Med Hyg 1991; 44:201-4.
34. Zhou Z, Xiao L, Branch OH, Kariuki S, Nahlen BL, Lal AA. Antibody responses to repetitive epitopes of the circumsporozoite protein, liver stage antigen-1, and merozoite surface protein-2 in infants residing in a Plasmodium falciparum-hyperendemic area of western Kenya. XIII. Asembo Bay Cohort Project. Am J Trop Med Hyg 2002; 66:7-12.
35. Alonso PL, Sacarlal J, Aponte JJ, et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 2005; 366:2012-8.
36. Alonso PL, Sacarlal J, Aponte JJ, et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004; 364:1411-20.
37. Ofulla AV, Moormann AM, Embury PE, Kazura JW, Sumba PO, John CC. Age-related differences in the detection of Plasmodium falciparum infection by PCR and microscopy, in an area of Kenya with holoendemic malaria. Ann Trop Med Parasitol 2005; 99:431-5.